Bilal Bashir

Be PRAGMATIC Be SIMPLE From Haffner to VESALIUS: we didn’t discover anything new… we finally accepted it. 📍 1888, Haffner (NEJM) already warned us: 👉 A patient with diabetes and no MI carries a risk similar to someone who already had one. nejm.org/doi/full/10.10… 📍 2026 VESALIUS (JAMA) just removes the last excuse: 👉 Even before clinically evident atherosclerosis, the risk is already biologically active. jamanetwork.com/journals/jama/… 👆 Let’s be honest: There are NO LOW-RISK patients with diabetes There are NO INTERMEDIATE-RISK patients with diabetes 👉 There are only: HIGH RISK VERY HIGH RISK (most of them, if you actually look closely) 📌 The problem is not classification. 📌 The problem is clinical denial and therapeutic inertia. We don’t undertreat diabetes because we lack evidence. 👉 We undertreat it because we are still thinking in outdated risk categories. Atherosclerosis starts early. Diabetes accelerates it. And we… keep labeling instead of acting. @society_eas @nationallipid

The genetic architecture of FCS is more complex and heterogeneous in the UK: - 12.9% of the tested are genetically confirmed FCS - Over half are LPL-FCS, but non-LPL FCS are equally common - Regional & ethnic variability gimopen.org/article/S2949-… @RareDiseases @heartukcharity

Neurodegeneration, neuropathy & familial chylomicronemia syndrome (FCS) — we report an under-recognised complication of this rare lipid disorder. share.google/wfDNNMUE5DlovA…

Our latest work shows that hypertriglyceridaemia alone can cause small fibre neuropathy and cardiac autonomic dysfunction. doi.org/10.1016/j.athe… @MFT_MRI @MFTnhs @heartukcharity

We reviewed how does HDL participate in atherogenesis? Antioxidant Activity Versus Role in Reverse Cholesterol Transport mdpi.com/3252632 #mdpiantioxidants via @antioxidants_OA

We quantified the clinical impact of variation on GH and IGF-1 measurements on the classification of acromegaly disease status in the UK academic.oup.com/ejendo/article… @safwaan_adam

Presented at #AHA24: In a large trial involving patients with acute myocardial infarction, 95% of whom had ST-segment elevation myocardial infarction, spironolactone did not reduce the risk of cardiovascular events. Full CLEAR trial results: nej.md/4ftkpIc

In the CLEAR randomized trial involving patients with acute myocardial infarction, colchicine did not decrease the risk of major adverse cardiovascular events over a median follow-up period of 3 years. Full trial results: nej.md/4i2U6dV

Nov. Featured Article: UK FCS registry: Higher pancreatitis risks but lower ASCVD rates in FCS vs. MCS; gene distribution varies by ethnicity ahajrnls.org/3YJy0VT

#FCS is an ultra-rare disorder causing extremely high triglycerides,with significant delays in diagnosis and unmet clinical needs.Thanks to everyone who stopped by on FCS Awareness Day to learn about it @ActionFCS @CheckOrphan @heartukcharity @MFTnhs @atherosociety @society_eas

Our latest article from UK FCS National Registry has been chosen as one of the two “Featured” articles in the November 2024 issue of @atvbahajournals ahajournals.org/doi/10.1161/AT…

HEART UK is delighted to announce the formation of the Early Career Cardiovascular Disease Prevention (ECCDP) Network designed to bring together junior & early-career HCPs & researchers to collaborate & share expertise. heartuk.org.uk/professional-n… #lipids

Hypertriglyceridaemia in absence of diabetes causes peripheral & cardiac autonomic neuropathy. @Neurodiab_eu @heartukcharity @OfficialUoM @CVD_MFT @MFT_Research

FCS leads to small fibre nerve damage, clinical neuropathy & early CAN @Neurodiab_eu @heartukcharity @CVD_MFT @RareDiseases @CheckOrphan

Join researchers & clinicians at #ISA2024. Don’t miss opportunity to expand network while discussing how precision med can prevent,detect & manage cardiometabolic diseases. Use code ISAABILAL50 for discounted reg isa2024oman.org @atherosociety @OslaOman @heartukcharity

Cardivascular risk extends beyond LDL-C, but are their any other therapeutic targets? Does lowering triglycerides help? frontiersin.org/journals/cardi…

📰 Congratulations to the ‘Balance' study team at @MFTnhs, led nationally by UK Lead, Prof Handrean Soran. The global research published in @NEJM into the rare genetic condition FCS has revealed the life-saving potential for new drug olezarsen. 👇 nejm.org/doi/10.1056/NE…

We presented 4 papers at 37th Annual HEART UK conference. @rarediseaseuk @heartukcharity @CVD_MFT @MFT_Research @MFTnhs #HUK #lipids

The 2nd talk by @drbilalbashir was on 'Hypertriglyceridaemia and Cardiovascular Autonomic Function in Patients Without Diabete Mellitus'

The first talk was by @drbilalbashir who presented his talk 'Genetic Landscape of Familial Chylomicronaemia Syndrome (FCS) and Multifactorial Chylomicronaemia Syndrome (MCS) in the UK